New targeted treatment modalities, including BRAF and MEK inhibitors as well as immune checkpoint inhibitors, have revolutionized the treatment of metastatic melanoma patients in the last decade [40, 71]. The gene discussed is MAP2K7; the disease is metastatic melanoma.